NVCR · NovoCure Ltd
$14.94
-0.98 (-6.16%)
At close · Oct 2
Return incl. dividend (before tax)
Market Cap
$1.84B
Shares
116.45M
Volume · Oct 2
1.71M
Avg daily vol (3M)
1.41M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$15.92
Open$15.81
Day$15.77–16.44
52W close$10.03–19.99
Avg vol 30d1.1M
Short int11.8M · 10.1% float · 11.5d
Short vol47%
Last earningsOct 29, 2026
DataJan 2020–Oct 2026
Filing10-Q · Jul 23
Up next
Next earnings release
Oct 29, 2026
Announced
· in 4 wks
Next earnings call
Oct 29, 2026
Scheduled
· in 4 wks
filed Jul 23, 2026
call held Jul 23, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
+13.9%
Trailing year
Short interest
10.1%
Latest settlement · 11.5 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Bearish
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.57
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+8%
above
Price vs 50-day avg
−5%
below
RSI (14)
43
neutral
MACD trend
Negative
52-week position
59%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−11%
trailing
6-month return
+50%
trailing
YTD return
+23%
this year
Relative strength
+38%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $17 › 200d $15 — 50d above 200d
Institutional flow
Distributing
-3% holders QoQ · +31 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
10.13% of float · ▲ +9.3% MoM · 11.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
218 holders — near 3-yr low, contrarian setup
Squeeze score
80
high risk · 0–100
Fundamentals
Revenue growth
+8%
Y/Y
Gross margin
75%
contracting
EPS growth
+22%
Y/Y
Free cash flow
$-75.7M
Balance sheet
$140.5M
net cash
Quant / Vol
risk profile
Volatility
80%
annualized · 1-yr
Max drawdown
−33%
past year
ATR
4.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Jul 23, 2026
Total net revenue
· full year 2026
Initiated
$710M – $725M
prior FY $655.35M
midpoint +9.5% Y/Y
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+8%
Bullish
Price vs 50-day avg
−5%
Neutral
RSI (14)
43
Neutral
MACD trend
Negative
Bearish
52-week position
59%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $17 › 200d $15 — 50d above 200d
Institutional flow
Distributing
-3% holders QoQ · +31 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
10.13% of float · ▲ +9.3% MoM · 11.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
218 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $10
Now $16 · 59%
Range high $20
vs 200-day avg +8%
vs 50-day avg -5%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $10.76M | Three months ended June 30, 2026 filing | — |
| Cost of revenues per active patient per month | $2,483 | Three months ended June 30, 2026 filing | — |
| Prescriptions received in period - United States | 418 | Three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NVCR
this stock
NovoCure Ltd
|
$1.84B | +23.1% | +8.3% | — | 10.1% |
|
ABT
Abbott Laboratories
|
$174.90B | -22.8% | +5.7% | 28.1 | 1.1% |
|
MDT
Medtronic plc
|
$113.38B | -10.0% | +8.4% | 21.8 | 1.3% |
|
SYK
Stryker Corp
|
$104.47B | -22.3% | +11.2% | 28.2 | 2.0% |
|
BSX
Boston Scientific Corp
|
$63.59B | -54.7% | +12.5% | 17.8 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NVCR | -1.7% | -10.7% | +50.5% | -0.2% | +23.1% |
| SPY | -0.4% | -0.2% | +12.4% | +0.2% | +12.0% |
| vs SPY | -1.3% | -10.6% | +38.0% | -0.4% | +11.1% |